These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15167167)

  • 1. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.
    Stallmach A; Giese T; Schmidt C; Meuer SC; Zeuzem SS
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):627-30. PubMed ID: 15167167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.
    Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
    J Crohns Colitis; 2012 Feb; 6(1):108-11. PubMed ID: 22261535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of adalimumab in infliximab-allergic patients.
    Youdim A; Vasiliauskas EA; Targan SR; Papadakis KA; Ippoliti A; Dubinsky MC; Lechago J; Paavola J; Loane J; Lee SK; Gaiennie J; Smith K; Do J; Abreu MT
    Inflamm Bowel Dis; 2004 Jul; 10(4):333-8. PubMed ID: 15475739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease.
    Diamanti A; Castro M; Papadatou B; Ferretti F; Gambarara M
    J Pediatr; 2002 May; 140(5):636-7; author reply 637. PubMed ID: 12032538
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction.
    Puchner TC; Kugathasan S; Kelly KJ; Binion DG
    Inflamm Bowel Dis; 2001 Feb; 7(1):34-7. PubMed ID: 11233658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.
    Riegert-Johnson DL; Godfrey JA; Myers JL; Hubmayr RD; Sandborn WJ; Loftus EV
    Inflamm Bowel Dis; 2002 May; 8(3):186-91. PubMed ID: 11979139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
    Cravo M; Silva R; Serrano M
    BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in inflammatory bowel disease: attention to adverse events.
    Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease.
    Panagi S; Palka W; Korelitz BI; Taskin M; Lessnau KD
    Inflamm Bowel Dis; 2004 May; 10(3):274-7. PubMed ID: 15290924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.